A Randomised, Single Centre, Double-blind, Two-period, Cross-over Trial in Healthy Subjects Investigating the Bioequivalence Between Subcutaneous Injections of Semaglutide Produced by Two Manufacturing Processes
Phase of Trial: Phase I
Latest Information Update: 28 Aug 2014
At a glance
- Drugs Semaglutide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Novo Nordisk
- 01 May 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 14 Feb 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 24 Jan 2013 New trial record